Candida albicans Flu1-mediated efflux of salivary histatin 5 reduces its cytosolic concentration and fungicidal activity

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1832-1839

  Li, Rui ^a   Kumar, Rohitashw ^a   Tati, Swetha ^a   Puri, Sumant ^a   Edgerton, Mira ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; HISTATIN 5; SPERMIDINE;

ARTICLE; BIOFILM; CANDIDA ALBICANS; FLU1 GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; GENE DELETION; GENE OVEREXPRESSION; MYCOTOXICOSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; TPO2 GENE;

ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; DRUG RESISTANCE, MULTIPLE; FUNGAL PROTEINS; HISTATINS; HUMANS; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPERMIDINE;

EID: 84875199113     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02295-12     Document Type: Article

References (59)

1. Shapiro RS, Robbins N, Cowen LE. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75:213-267.
2. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A, Barcelona Candidemia Project Study Group. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
4. Paphitou NI, Ostrosky-Zeichner L, Rex JH. 2005. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med. Mycol. 43:235-243.
5. Spellberg BJ, Filler SG, Edwards JE. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
7. Casalinuovo IA, Di Francesco P, Garaci E. 2004. Fluconazole resistance in Candida albicans: a review of mechanisms. Eur. Rev. Med. Pharmacol. Sci. 8:69-77.
8. Cowen LE, Steinbach WJ. 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot. Cell 7:747-764.
9. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. 2010. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9:719-727.
10. Mansfield BE, Oltean HN, Oliver BG, Hoot SJ, Leyde SE, Hedstrom L, White TC. 2010. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 6:e1001126. doi:10.1371/journal.ppat. 1001126.
11. Hitchcock CA. 1991. Cytochrome-P-450-dependent 14-alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem. Soc. Trans. 19:782-787.
12. Vanden Bossche H, Marichal P, Odds FC. 1994. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2:393-400.
13. Joseph-Horne T, Hollomon DW. 1997. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol. Lett. 149:141-149.
14. Anderson JB. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3:547-556.
15. Cowen LE. 2008. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6:187-198.
16. Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, Niimi M, Monk BC. 2007. Candida albicans drug resistance-another way to cope with stress. Microbiology 153:3211-3217.
17. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42: 2932-2937.
18. Harry JB, Song JL, Lyons CN, White TC. 2002. Transcription initiation of genes associated with azole resistance in Candida albicans. Med. Mycol. 40:73-81.
19. Prasad R, Dewergifosse P, Goffeau A, Balzi E. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
20. White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
21. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291-321.
22. Morschhauser J. 2010. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet. Biol. 47:94-106.
23. Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405-416.
24. Sanglard D, Ischer F, Monod M, Bille J. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
25. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
26. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martínez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
27. Pasrija R, Banerjee D, Prasad R. 2007. Structure and function analysis of CaMdr1p, a major facilitator superfamily antifungal efflux transporter protein of Candida albicans: identification of amino acid residues critical for drug/H+ transport. Eukaryot. Cell 6:443-453.
28. Dias PJ, Seret ML, Goffeau A, Correia IS, Baret PV. 2010. Evolution of the 12-spanner drug:H+ antiporter DHA1 family in hemiascomycetous yeasts. OMICS 14:701-710.
29. Teixeira MC, Cabrito TR, Hanif ZM, Vargas RC, Tenreiro S, Sá-Correia I. 2011. Yeast response and tolerance to polyamine toxicity involving the drug:H+ antiporter Qdr3 and the transcription factors Yap1 and Gcn4. Microbiology 157:945-956.
30. Chen LM, Xu YH, Zhou CL, Zhao J, Li CY, Wang R. 2010. Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. J. Int. Med. Res. 38:536-545.
31. Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, Godoy Martinez PC, Goldman MH, Colombo AL. 2004. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn. Microbiol. Infect. Dis. 50:25-32.
32. White TC, Pfaller MA, Rinaldi MG, Smith J, Redding SW. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl 1):S102-S109.
33. Calabrese D, Bille J, Sanglard D. 2000. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 146:2743-2754.
34. Nelissen B, Mordant P, Jonniaux JL, DeWachter R, Goffeau A. 1995. Phylogenetic classification of the major superfamily of membrane transport facilitators, as deduced from yeast genome sequencing. FEBS Lett. 377:232-236.
35. Kashiwagi K, Igarashi K. 2011. Identification and assays of polyamine transport systems in Escherichia coli and Saccharomyces cerevisiae. Methods Mol. Biol. 720:295-308.
36. Raj PA, Edgerton M, Levine MJ. 1990. Salivary histatin 5: dependence of sequence, chain length, and helical conformation for candidacidal activity. J. Biol. Chem. 265:3898-3905.
37. Castagnola M, Inzitari R, Rossetti DV, Olmi C, Cabras T, Piras V, Nicolussi P, Sanna MT, Pellegrini M, Giardina B, Messana I. 2004. A cascade of 24 histatins (histatin 3 fragments) in human saliva-suggestions for a pre-secretory sequential cleavage pathway. J. Biol. Chem. 279:41436-41443.
38. Koshlukova SE, Araujo MWB, Baev D, Edgerton M. 2000. Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of Candida albicans. Infect. Immun. 68:6848-6856.
39. Vylkova S, Jang WS, Li W, Nayyar N, Edgerton M. 2007. Histatin 5 initiates osmotic stress response in Candida albicans via activation of the Hog1 mitogen-activated protein kinase pathway. Eukaryot. Cell 6:1876-1888.
40. Jang WS, Bajwa JS, Sun JN, Edgerton M. 2010. Salivary histatin 5 internalization by translocation, but not endocytosis, is required for fungicidal activity in Candida albicans. Mol. Microbiol. 77:354-370.
41. Kumar R, Chadha S, Saraswat D, Bajwa JS, Li RA, Conti HR, Edgerton M. 2011. Histatin 5 uptake by Candida albicans utilizes polyamine transporters Dur3 and Dur31 proteins. J. Biol. Chem. 286:43748-43758.
42. Tomitori H, Kashiwagi K, Sakata K, Kakinuma Y, Igarashi K. 1999. Identification of a gene for a polyamine transport protein in yeast. J. Biol. Chem. 274:3265-3267.
43. Tomitori H, Kashiwagi K, Asakawa T, Kakinuma Y, Michael AJ, Igarashi K. 2001. Multiple polyamine transport systems on the vacuolar membrane in yeast. Biochem. J. 353:681-688.
44. Goffeau A, Barrell BG, Bussey H, Davis RW, Dujon B, Feldmann H, Galibert F, Hoheisel JD, Jacq C, Johnston M, Louis EJ, Mewes HW, Murakami Y, Philippsen P, Tettelin H, Oliver SG. 1996. Life with 6000 genes. Science 274:546, 563-567.
45. Desmoucelles C, Pinson B, Saint-Marc C, Daignan-Fornier B. 2002. Screening the yeast "disruptome" for mutants affecting resistance to the immunosuppressive drug, mycophenolic acid. J. Biol. Chem. 277:27036-27044.
46. do Valle Matta MA, Jonniaux JL, Balzi E, Goffeau A, van den Hazel B. 2001. Novel target genes of the yeast regulator Pdr1p: a contribution of the TPO1 gene in resistance to quinidine and other drugs. Gene 272:111-119.
47. Uemura T, Tachihara K, Tomitori H, Kashiwagi K, Igarashi K. 2005. Characteristics of the polyamine transporter TPO1 and regulation of its activity and cellular localization by phosphorylation. J. Biol. Chem. 280: 9646-9652.
48. Helmerhorst EJ, Hodgson R, van 't Hof W, Veerman EC, Allison C, Nieuw Amerongen AV. 1999. The effects of histatin-derived basic antimicrobial peptides on oral biofilms. J. Dent. Res. 78:1245-1250.
49. Jang WS, Li XS, Sun JN, Edgerton M. 2008. The P-113 fragment of histatin 5 requires a specific peptide sequence for intracellular translocation in Candida albicans, which is independent of cell wall binding. Antimicrob. Agents Chemother. 52:497-504.
50. Li XS, Reddy MS, Baev D, Edgerton M. 2003. Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J. Biol. Chem. 278:28553-28561.
51. Pusateri CR, Monaco EA, Edgerton M. 2009. Sensitivity of Candida albicans biofilm cells grown on denture acrylic to antifungal proteins and chlorhexidine. Arch. Oral Biol. 54:588-594.
52. Valdes-Santiago L, Cervantes-Chavez JA, Leon-Ramirez CG, Ruiz-Herrera J. 2012. Polyamine metabolism in fungi with emphasis on phytopathogenic species. J. Amino Acids 2012:837932. doi:10.1155/2012/837932.
53. Shukla S, Saini P, Smriti, Jha S, Ambudkar SV, Prasad R. 2003. Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot. Cell 2:1361-1375.
54. Gebhard S. 2012. ABC-transporters of antimicrobial peptides in Firmicutes bacteria-phylogeny, function and regulation. Mol. Microbiol. 86: 1295-1317.
55. Tsai H, Bobek LA. 1997. Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and-resistant Candida species. Antimicrob. Agents Chemother. 41:2224-2228.
56. Znaidi S, Barker KS, Weber S, Alarco AM, Liu TT, Boucher G, Rogers PD, Raymond M. 2009. Identification of the Candida albicans Cap1p regulon. Eukaryot. Cell 8:806-820.
57. Porat Z, Wender N, Erez O, Kahana C. 2005. Mechanism of polyamine tolerance in yeast: novel regulators and insights. Cell. Mol. Life Sci. 62: 3106-3116.
58. Davis RH, Ristow JL. 1991. Polyamine toxicity in Neurospora crassa: protective role of the vacuole. Arch. Biochem. Biophys. 285:306-311.
59. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.